Details

Autor(en) / Beteiligte

• Calderon-Gonzalez, R
• Terán-Navarro, H
• García, I
• Marradi, M
• Salcines-Cuevas, D
• Yañez-Diaz, S
• Solis-Angulo, A
• Frande-Cabanes, E
• Fariñas, M. C
• Garcia-Castaño, A
• Gomez-Roman, J
• Penades, S
• Rivera, F
• Freire, J
• Álvarez-Domínguez, C

Titel

Gold glyconanoparticles coupled to listeriolysin O 91-99 peptide serve as adjuvant therapy against melanomaElectronic supplementary information (ESI) available. See DOI: 10.1039/c7nr02494k

Erscheinungsjahr

2017-08

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Dendritic cell-based (DC-based) vaccines are promising immunotherapies for cancer. However, several factors, such as the lack of efficient targeted delivery and the sources and types of DCs, have limited the efficacy of DCs and their clinical potential. We propose an alternative nanotechnology-based vaccine platform with antibacterial prophylactic abilities that uses gold glyconanoparticles coupled to listeriolysin O 91-99 peptide (GNP-LLO 91-99 ), which acts as a novel adjuvant for cancer therapy. GNP-LLO 91-99 , when used to vaccinate mice, exhibited dual antitumour activities, namely, the inhibition of tumour migration and growth and adjuvant activity for recruiting and activating DCs, including those from melanoma patients. GNP-LLO 91-99 nanoparticles caused tumour apoptosis and induced antigen- and melanoma-specific cytotoxic Th1 responses ( P ≤ 0.5). We propose this adjuvant nanotherapy for preventing the progression of the first stages of melanoma. Dendritic cell-based (DC-based) vaccines are promising immunotherapies for cancer.